Related Experiment Video
Updated: Apr 7, 2026
05:30
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
30.0K
S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury
Shruti V Kabadi1, Bogdan A Stoica1, Danna B Zimmer2
1Center for Shock, Trauma and Anesthesiology Research (STAR) and Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Summary
Inhibiting S100B protein after traumatic brain injury (TBI) reduced brain damage and improved memory. This suggests S100B is a potential therapeutic target for TBI recovery.
Area of Science:
- Neuroscience
- Immunology
- Traumatic Brain Injury Research
Background:
- Neuroinflammation post-traumatic brain injury (TBI) contributes to long-term tissue damage and functional deficits.
- Elevated circulating S100B levels after TBI serve as a potential biomarker.
- S100B, released by activated astrocytes, can exacerbate microglial activation and neuroinflammation.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting S100B in a mouse model of TBI.
- To determine the role of S100B in TBI-induced neuroinflammation, neuronal loss, and functional impairment.
Main Methods:
- Utilized a controlled cortical impact model in S100B knockout mice and wild-type mice treated with S100B-neutralizing antibodies.
- Assessed lesion volume, cognitive function (retention memory), sensorimotor deficits, microglial activation, and neuronal survival.
- Examined S100B's effect on microglial activation in vitro and potential interaction with the receptor for advanced glycation end products (AGER).
Main Results:
- S100B inhibition significantly reduced TBI-induced lesion volume and improved retention memory.
- Neutralizing S100B antibodies attenuated microglial activation, reduced sensorimotor deficits, and enhanced neuronal survival.
- S100B did not directly modulate microglial activation in vitro, and direct S100B-AGER interaction was not supported post-TBI.
Conclusions:
- S100B plays a significant role in TBI-induced neuroinflammation, neuronal loss, and functional deficits.
- Targeting S100B presents a promising therapeutic strategy for mitigating TBI consequences.
- Further research is required to fully elucidate the mechanisms of S100B-mediated neuroinflammation in TBI.
